Thymosin Beta-4 Sulfoxide

Wound Healing & Regeneration

Tß4 SulfoxideTB4-SO

Overview

Thymosin Beta-4 Sulfoxide (Tß4 Sulfoxide, TB4-SO) is a naturally occurring peptide derivative of Thymosin Beta-4, which is a small protein found in many tissues of the body. It is formed through the oxidation of Thymosin Beta-4, resulting in the addition of a sulfoxide group. This compound is of interest due to its potential role in tissue repair and regeneration. Researchers synthesize Thymosin Beta-4 Sulfoxide through chemical modification of Thymosin Beta-4, allowing for controlled studies of its biological effects. The primary research areas for Thymosin Beta-4 Sulfoxide include wound healing and tissue regeneration. Researchers have observed that it may enhance the repair of damaged tissues, reduce inflammation, and promote cell migration. These effects have been studied in various models of injury, including skin wounds and cardiac tissue damage. The mechanism of action of Thymosin Beta-4 Sulfoxide involves modulation of actin dynamics, which is crucial for cell movement and tissue repair. It also interacts with signaling pathways involved in inflammation and cell survival, such as the PI3K/Akt pathway. Pharmacokinetic properties of Thymosin Beta-4 Sulfoxide are not well-documented, with limited data available on its half-life and stability. Researchers have noted that its bioavailability may vary depending on the route of administration, but specific values are largely unknown. Current research on Thymosin Beta-4 Sulfoxide is ongoing, with studies focusing on its potential therapeutic applications in regenerative medicine. It is not yet approved as a medicinal product by major regulatory agencies, and its use is primarily confined to research settings.

Mechanism of Action

Thymosin Beta-4 Sulfoxide is believed to exert its effects by modulating actin filament dynamics, which are essential for cell motility and tissue repair. It also influences the PI3K/Akt signaling pathway, which plays a role in cell survival and inflammation reduction.

Half-Life

Intranasal	Not applicable
Oral	Poor bioavailability

Pharmacokinetic data is limited, with variability expected based on administration route.

Storage

Lyophilized

Stable for 2+ years at -20°C, 12 months at 4°C

Reconstituted

Use within 14 days when refrigerated at 4°C

Avoid

Avoid repeated freeze-thaw cycles, direct light

Solvent

Bacteriostatic water or sterile saline recommended

Solubility

Thymosin Beta-4 Sulfoxide is soluble in water and DMSO.

Legal Status

🇩🇪DE

Not approved as a medicinal product. Not a controlled substance. Sale as research chemical is a legal grey area.

🇺🇸US

Not approved by the FDA as a medicinal product. Not scheduled by the DEA.

🇦🇺AU

Not listed in the TGA schedules.

🇬🇧UK

Not approved by the MHRA as a medicinal product.

Legal status information is provided for general reference only and may not reflect the most current regulatory changes. Always verify with official government sources before making any decisions.

3 Research Publications

Thymosin beta4: actin regulation and more.

Unknown

Annals of the New York Academy of Sciences · 2007

Researchers studied thymosin beta(4), a protein involved in regulating actin, a key component of cell structure. They found that thymosin beta(4) forms a complex with actin and another protein, profilin, which influences how these proteins interact and function. The study also revealed that certain chemical changes can affect the structure and binding ability of thymosin beta(4).

Researchers found that thymosin beta(4) forms a ternary complex with actin and profilin, affecting their interactions.
The study observed that the presence of TMAO stabilizes thymosin beta(4) and increases its binding affinity to actin.
Researchers noted that oxidation alters the structure of thymosin beta(4), impacting its properties and interactions.

PubMed

Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids.

Animal

Nature medicine · 1999

Researchers found that a molecule called thymosin beta 4 sulfoxide, produced by immune cells in the presence of glucocorticoids, can reduce inflammation. This discovery suggests that it may provide the benefits of steroid treatments without the harmful side effects. The study highlights a new way to potentially manage inflammatory diseases.

Thymosin beta 4 sulfoxide is generated by monocytes when glucocorticoids are present.
This molecule inhibits the movement of neutrophils, a type of immune cell involved in inflammation.
In animal tests, thymosin beta 4 sulfoxide effectively reduced swelling caused by inflammation.

PubMed

Interactions of beta-thymosins, thymosin beta 4-sulfoxide, and N-terminally truncated thymosin beta 4 with actin studied by equilibrium centrifugation, chemical cross-linking and viscometry.

Unknown

European journal of biochemistry · 1995

Researchers studied how different forms of beta-thymosins interact with a protein called actin, which is important for muscle function. They found that these beta-thymosins can inhibit the formation of actin filaments under certain conditions, with specific amino acids playing a crucial role in this interaction.

All beta-thymosins examined inhibit the polymerization of actin into filaments under high salt conditions.
Oxidation and truncation of thymosin beta 4 reduce its ability to bind to actin, with significant loss of interaction when certain amino acids are removed.
Only the oxidized form of thymosin beta 4 effectively inhibits actin polymerization, but requires a much higher concentration compared to the unmodified beta-thymosin.

PubMed

Track Thymosin Beta-4 Sulfoxide in PepStack

Log your research cycles, set reminders and visualize serum levels.

Download on theApp Store Get it onGoogle Play

This page is for informational and research purposes only. All information is based on published scientific literature. Nothing on this page constitutes medical advice or replaces consultation with a qualified healthcare professional.